US FDA And Sponsors Resolve Disclosure Issues On Complex Trial Design Pilot Projects
Executive Summary
Agency officials can now discuss the ideas that have been accepted, though not in great detail.
You may also be interested in...
US FDA Hopes Food, Inspection Office Reorg Bolsters Innovative Clinical Trial Adoption
Ensuring inspectors understand the innovative trial designs in use before an inspection will be important to increasing industry confidence in their use, CDER Director Patrizia Cavazzoni said.
Boosting Complex Innovative Designs In Clinical Trials: What The Pilots Show
Lilly representative suggests having more informal communication with FDA and consistent feedback across divisions. The firm had a positive experience participating in CID pilot with master protocol for chronic pain therapies.
US FDA Solicits Comments On Barriers To Innovative Trial Design Implementation
In admitting problems, the FDA creates a docket for comments and will convene a public workshop in the spring on why the clinical trial innovation is not more widespread.